Joan Mannick, Tornado Therapeutics CEO

No­var­tis vet is get­ting an­oth­er shot at mTOR fol­low­ing the im­plo­sion of a longevi­ty pi­o­neer

One of the up­starts in the longevi­ty field has roped in some fresh dis­cov­ery as­sets out of No­var­tis — along with a No­var­tis vet to head up their new sub­sidiary.

New York-based Cam­bri­an Bio­phar­ma has li­censed rights to mTOR pro­grams from the No­var­tis In­sti­tutes for Bio­Med­ical Re­search — a Jay Brad­ner-led group that has been known to spin out as­sets from time to time when dis­cov­ery projects don’t nec­es­sar­i­ly fit right in­to their core R&D fo­cus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.